![](https://d3ilqtpdwi981i.cloudfront.net/YNHIB7-ySz3SKer8A_22z0XEB1c=/0x0:152x196/425x550/smart/https://bepress-attached-resources.s3.amazonaws.com/uploads/31/fe/43/31fe4399-76f7-4872-9d97-ff60b148799e/cov200h.gif)
Article
Survival Time is Problematic as an Indicator of an anti- AML Drug’s Effectiveness
Clinical Lymphoma, Myeloma & Leukemia
(2017)
Disciplines
Publication Date
January 9, 2017
DOI
10.1016/j.clml.2017.07.053
Citation Information
Carole Shaw, Shelly Hager, Mary-Elizabeth Percival, Roland Walter, et al.. "Survival Time is Problematic as an Indicator of an anti- AML Drug’s Effectiveness" Clinical Lymphoma, Myeloma & Leukemia Vol. 17 (2017) Available at: http://works.bepress.com/kathleen_shannondorcy/14/